The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3751-3759

  Souvatzoglou, Michael ^a   Weirich, Gregor ^a   Schwarzenboeck, Sarah ^a   Maurer, Tobias ^a   Schuster, Tibor ^a   Bundschuh, Ralph Alexander ^a   Eiber, Matthias ^a   Herrmann, Ken ^a   Kuebler, Hubert ^a   Wester, Hans Juergen ^a   Hoefler, Heinz ^a   Gschwend, Juergen ^a   Schwaiger, Markus ^a   Treiber, Uwe ^a   Krause, Bernd Joachim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; CHOLINE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; SENSITIVITY AND SPECIFICITY; CANCER STAGING; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING;

AGED; CHOLINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; SENSITIVITY AND SPECIFICITY;

EID: 79957916013     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2093     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007;57:90-104.
3. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159:1247-50. (Pubitemid 28172807)
4. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-4. (Pubitemid 30481935)
5. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. Am J Roentgenol 2004;183:1079-83. (Pubitemid 44185100)
6. Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007;244:797-806.
7. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53. Review.
8. Kim CK, Park BK. Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr 2008;32:163-72. Review.
9. Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging. 2009;53:245-68. Review.
10. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999 Dec;29:623-9.
11. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997;17:1455-60.
12. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603. (Pubitemid 32694969)
13. Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol 1993;150:2019-24. (Pubitemid 24350856)
14. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-3.
15. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4. (Pubitemid 29062961)
16. 11C-choline PET/CT. J Nucl Med 2006;47:1249-54.
17. 18F]- fluorocholine positron emission tomography. J Urol 2005;173:252-5.
18. 11C]choline PET/CT with histopathologic stepsection analysis. J Nucl Med 2005;46:1642-9.
19. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8. (Pubitemid 40571106)
20. 11C]choline. J Label Compd Radiopharm 2000;43:195-203.
21. Martinez MJ, Bercier Y, Schwaiger M, Ziegler SI. PET/CT Biograph Sensation 16 Performance improvement using faster electronics. Nuklearmedizin 2006;45:126-33. (Pubitemid 44047833)
22. Beer AJ, Wieder HA, Lordick F, Ott K, Fischer M, Becker K, et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006 May;239:472-80.
23. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models Biometrika. 1986;73:13-22.
24. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005 Jul;32:742-8. (Pubitemid 41125415)
25. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. [11C]choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-60. (Pubitemid 44142558)
26. 11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065-73.
27. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317-24.
28. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668-73.